

Register
by August 7
and SAVE
up to
\$350!

 Cambridge Healthtech Institute's
Seventh International

Discovery on TARGET

Diverse Pathways • Multiple Targets • One Event



BOSTON

November 2-4, 2009
InterContinental Hotel, Boston, MA

KEYNOTE PRESENTERS



David Clapham, M.D., Ph.D., Howard Hughes Medical Institute



Michael Dabrowski, Ph.D., AstraZeneca



Gregory J. Kaczorowski, Ph.D., School; Robert Wood Johnson Medical School



John M. Maraganore, Ph.D., Alnylam Pharmaceuticals, Inc.



Graeme Milligan, Ph.D., University of Glasgow



Steven E. Nissen, M.D., M.A.C.C., Cleveland Clinic Foundation

David Root, Ph.D., The RNAi Consortium Broad Institute of MIT and Harvard

Anja J. Stauber, Ph.D., DABT, Eli Lilly and Company

Eric M. Verdin, M.D., University of California, San Francisco

Concurrent Tracks November 2 - 3

Seventh Annual

● RNAi for Screening Cellular Pathways and Targets

Third Annual

● HDAC Inhibitors

Fourth Annual

● Ion Channels as Therapeutic Targets

Fourth Annual

● GPCR-Based Drug Discovery

Concurrent Tracks November 3 - 4

Third Annual

● RNAi for Developing Targeted Therapeutics

Third Annual

● Kinase Inhibitors

Second Annual

● Targeting Diabetes with Novel Therapeutics

SHORT COURSES:

Sunday, November 1

Strategies for Effective RNAi Screens

Targeting GPCRs and Ion Channels with Antibodies

Strategies for Optimizing RNAi Delivery

Combating Diabetes with Strategies for Enhanced Pancreatic Beta Cell Survival and Regeneration

Structure-Based Design of Ion Channels

Cardiovascular Safety in Drug Development - From Preclinical to Phase I

Corporate Sponsors:



Lead Sponsoring Publications:



Conference-at-a-Glance

SUNDAY, NOVEMBER 1

11:30 am–12:00 pm	Registration
12:00 pm–3:00 pm	CONCURRENT SHORT COURSES 1 and 2
2:00 pm–3:30 pm	Registration
3:30 pm–6:30 pm	CONCURRENT SHORT COURSES 3/4/5/6
4:30 pm–6:30 pm	Main Conference Early Registration

MONDAY, NOVEMBER 2

7:00 am–8:30 am	Registration and Morning Coffee
8:30 am–10:10 am	CONCURRENT TRACKS 1/2/3/4
10:10 am–10:40 am	Grand Opening Coffee Break in the Exhibit Hall
10:40 am–12:40 pm	CONCURRENT TRACKS 1/2/3/4
12:40 pm–2:20 pm	Luncheon Presentations or Lunch on Your Own
2:20 pm–3:55 pm	CONCURRENT TRACKS 1/2/3/4
3:55 pm–4:30 pm	Networking Refreshment Break in the Exhibit Hall
4:30 pm–5:45 pm	CONCURRENT TRACKS 1/2/3/4
5:30 pm–7:00 pm	Happy Hour in the Exhibit Hall

TUESDAY, NOVEMBER 3

7:30 am–8:30 am	Continental Breakfast Breakout Discussion Sessions
8:30 am–9:40 am	CONCURRENT TRACKS 1/2/3/4
9:40 am–10:40 am	Networking Coffee Break in the Exhibit Hall
10:40 am–12:40 pm	CONCURRENT TRACKS 1/2/3/4
12:40 pm	Close of Tracks 1/2/3/4
1:00 pm–2:00 pm	Registration
2:00 pm–3:40 pm	CONCURRENT TRACKS 5/6/7
3:40 pm–4:20 pm	Networking Refreshment Break in the Exhibit Hall
4:20 pm–6:20 pm	CONCURRENT TRACKS 5/6/7

WEDNESDAY, NOVEMBER 4

7:30 am–8:30 am	Continental Breakfast Breakout Discussion Sessions
8:35 am–10:10 am	CONCURRENT TRACKS 5/6/7
10:10 am–10:55 am	Networking Coffee Break in the Exhibit Hall
10:55 am–12:25 pm	CONCURRENT TRACKS 5/6/7
12:25 pm–1:55 pm	Luncheon Presentations or Lunch on Your Own
1:55 pm–3:00pm	CONCURRENT TRACKS 5/6/7
3:00 pm–3:40 pm	Networking Ice Cream Refreshment Break in Exhibit Hall (Last Chance for Viewing)
3:40 pm–5:10 pm	CONCURRENT TRACKS 5/6/7
5:10 pm	Close of Discovery on Target Summit

HOTEL & TRAVEL INFORMATION

Conference Hotel:

InterContinental Hotel
510 Atlantic Avenue
Boston, MA 02210
Tel: 617-747-1000
Fax: 617-217-5190

Discounted Room Rate: \$249 s/d
Room rate includes complimentary internet access
Discounted Room Rate Cut-off Date: October 5, 2009

Please visit our website or call the hotel directly to reserve your sleeping accommodations. Identify yourself as a Cambridge Healthtech Institute conference attendee to receive the reduced room rate. Reservations made after the cut-off date or after the group room block has been filled (whichever comes first) will be accepted on a space-and-rate-availability basis. Rooms are limited, so please book early.

Flight Discounts:

To receive a 5% or greater discount on all American Airline flights please use one of the following methods:

- Call 1-800-433-1790 (authorization code A4819SS).
- Go online at www.aa.com (enter A4819SS in promotion discount box).
- Contact our designated travel agent, Wendy Levine, at 1-800-336-5248 ext. 137.

Car Rental Discounts:

Special discount rentals have been established with AVIS for this conference. Please call AVIS directly at 800-331-1600 and you must reference our Avis Worldwide Discount (AWD) Number J868190.



CHI's Intro-Net: Networking at its Best!

*Maximize Your Experience Onsite
at Discovery On Target!*

The Intro-Net offers you the opportunity to set up meetings with selected attendees before, during and after this conference, allowing you to connect to the key people that you want to meet. This online system was designed with your privacy in mind and is only available to registered session attendees of this event. Registered conference attendees will receive more information on how to access the Intro-Net in the weeks leading up to the event!



12:00 pm – 3:00 pm

Strategies for Effective RNAi Screens (SC1)

This course is designed to provide in-depth information on how to go about setting up RNAi screening experiments and how to design assays for getting optimal results. The challenges working with different types of molecules i.e. siRNAs, shRNAs and the delivery systems to get them into the appropriate cells and tissues will be discussed. The instructors will also provide their input on best practices for the execution of experiments and interpretation of results when dealing with complex biology and informatics.

Topics to be covered:

- Overview of assay designs for siRNA and shRNA screens
- Testing and validating methods for RNA delivery
- Use of appropriate reagents and cell types
- Implementing proper quality control
- Minimizing cytotoxicity and off-target effects
- Data analysis and statistical considerations

Instructor(s):

Christophe J. Echeverri, Ph.D., CEO/CSO, Cenix BioScience GmbH
 Karol Kozak, Database Handling Unit, High Content Screening, LMC-RISC, ETH Zurich
 Caroline Shamu, Ph.D., Director, ICCB-Longwood Screening Facility, Harvard Medical School

Targeting GPCRs and Ion Channels with Antibodies (SC2)

This course is designed to be interactive and provide an in-depth update on the potentials and challenges of developing mAB candidates as therapeutics for conditions involving membrane proteins.

Topics to be covered:

- Pros and cons of targeting multi-spanning membrane proteins with antibody approaches
- Basic screening technologies for mAB against multi-spanners
- GPCR challenges such as expression level, post-translational modifications and oligomerization
- Ion channel specific methodologies
- Optimizing leads
- Case studies of clinical candidates

Instructor(s):

Tajib A. Mirzabekov, Ph.D., President & Chief Executive Officer, MSM Protein Technologies, Inc.
 Rajan Dighe, Ph.D., Professor, Molecular Reproduction, Development and Genetics, Indian Institute of Science
 Markus Delling, Ph.D., Instructor, Howard Hughes Medical Institute and Childrens Hospital Boston Cardiovascular Research, Harvard Medical School

3:30 pm – 6:30 pm

Strategies for Optimizing RNAi Delivery (SC3)

This course is designed to provide both the beginner and the expert with a comprehensive overview of current and emerging delivery systems and formulations facilitating RNAi delivery. Various methods for RNAi delivery such as viral vectors, liposomes, nanoparticles, chemical conjugates and other commonly used techniques will be compared and contrasted for different applications. The instructors will also discuss the challenges associated with RNAi delivery, both in vitro and in vivo, and offer guidance based on their knowledge and expertise in the field.

Topics to be covered:

- Testing and validating methods for delivery
- Overview of viral and non-viral vector systems
- Chemical methods of improving delivery
- New formulations to optimize delivery
- Minimizing cytotoxicity and off-target effects
- Examining tissue distribution and safety profiles

Instructor(s):

Roger Adami, Ph.D., Associate Director, Molecular Pharmaceutics, MDRNA, Inc.
 Derek M. Dykxhoorn, Ph.D., Assistant Professor of Human Genetics and Microbiology and Immunology, University of Miami School of Medicine
 Muthiah Manoharan, Ph.D., Vice President, Drug Discovery, Alnylam Pharmaceuticals, Inc.

Structure-Based Design of Ion Channels (SC5)Topics to be covered:

- Overview of current technologies
- Human vs animal channels – how comparable are they?
- High-throughput screening of ion channel inhibitors
- Automated Patch Clamp for Ion Channel Screenings
- Channel Gating of Potassium Channels

Instructors:

Chris Mathes, Ph.D., Vice-president & General Manager, Sophion Bioscience, Inc.
 Dan Minor, Ph.D., Associate Professor, Departments of Biochemistry & Biophysics and Cellular & Molecular Pharmacology; Investigator, Cardiovascular Research Institute, California Institute for Quantitative Biomedical Research, University of California, San Francisco

*Separate Registration Required

Sponsoring Publications:

Genome Technology



DiscoveryOnTarget.com

Online: www.DiscoveryOnTarget.comEmail: reg@healthtech.com

Fax: 781-972-5425

Track 1: RNAi For Screening Cellular Pathways and Targets

How to Best Utilize RNAi as a Tool for Functional Screening

November 2-3, 2009

SUNDAY, NOVEMBER 1

Recommended Short Courses*

12:00 pm - 3:00 pm Strategies for Effective RNAi Screens (SC1)*

3:30 pm - 6:30 pm Strategies to Optimize RNAi Delivery (SC3)*

*Separate Registration Required; Please See Page 3 for Details

MONDAY, NOVEMBER 2

7:00 am Registration and Morning Coffee

EXPLORING GENOME-WIDE RNAi SCREENS

8:30 Chairperson's Opening Remarks

Norbert Perrimon, Ph.D., Professor, Department of Genetics, Harvard Medical School

8:40 Efficient Vectors for *in vivo* RNAi and Construction of a *Drosophila* Genome-wide Transgenic RNAi Collection

Norbert Perrimon, Ph.D., Professor, Department of Genetics, Harvard Medical School

9:10 Genome-wide siRNA Gain-of-Function Screen for Modulators of the miRNA Pathway

Hakim Djaballah, Ph.D., Director, HTS Core Facility, Memorial Sloan Kettering Cancer Center

9:40 Genome-scale RNAi-based Screening to Identify Flavivirus Host Factors in Insects and Humans

James L. Pearson, Ph.D., Manager, RNAi Screening Facility, Center for RNA Biology, Duke University Medical Center

10:10 Grand Opening Coffee Break in the Exhibit Hall

10:40 Title to be Announced

Stephen Elledge, Ph.D., Department of Genetics, Center for Genetics and Genomics, Harvard Medical School

11:10 Genome-wide shRNA Search for Effector Function of mTOR Addicted Growth

Christoph Moroni, M.D., Professor, Department of Biochemistry, University of Basel

11:40 Title to be Announced

Michael Green, M.D., Ph.D., Professor, Gene Function and Expression and Molecular Medicine, University of Massachusetts Medical School

12:10 pm Genome-scale RNAi Screens Identify Loss of Function Phenotypes

James Goldmeyer, Ph.D., Field Application Scientist, Thermo Fisher Scientific



12:40 Luncheon Presentation
Next Generation siRNAs—Do They Really Improve RNAi Screening Results?

Susan Magdaleno, Ph.D., Senior Manager, Scientists, Life Technologies, Applied Biosystems



FOCUSED RNAi SCREENS FOR IDENTIFYING TARGETS

2:20 Chairperson's Remarks

Alex Gaither Ph.D., Research Investigator II, Developmental and Molecular Pathways, Novartis Institutes for Biomedical Research

2:25 Using Targeted siRNA Screens to Identify Novel Regulators of Viral Replication

Alex Gaither, Ph.D., Biomedical Research Investigator II, Novartis Institutes for Biomedical Research

2:55 Combining Parallel Chemical and RNAi Screens in Physiologically Relevant Cell Models to Identify Drug Targets

John N. Feder, Ph.D., Associate Director, Genome Biology, Applied Genomics, Bristol Myers Squibb Co.

3:25 Strengthening Oncology Pipeline Using RNAi Technology: From Target Discovery to Therapy

Yu Shen, Ph.D., Senior Group Leader, siRNA Therapeutics, Abbott Laboratories

3:55 Networking Refreshment Break in the Exhibit Hall

4:30 From RNAi Screens to Molecular Function: A Systematic Pipeline for Gene Function in Mammalian Cells

Frank Buchholz, Ph.D., Group Leader, Max Planck Institute for Molecular Cell Biology and Genetics

5:00 Identification of Synthetic Lethal Targets of Oncogenic KRAS Using Systematic RNA Interference

David Barbie, M.D., Assistant in Medicine, Massachusetts General Hospital and Dana-Farber Cancer Institute

5:30 Genome-Wide Screening with a Pooled shRNA Library for the Surface Receptor of Murine IgG3

Andre Nicola, MD, Research Associate, Department of Microbiology and Immunology, Albert Einstein College of Medicine



6:00 Happy Hour in the Exhibit Hall

7:00 Close of Day

TUESDAY, NOVEMBER 3

7:30 am Continental Breakfast Breakout Discussion Sessions

DIVERSIFYING RNAi SCREENING APPLICATIONS

8:30 Chairperson's Remarks

Christophe J. Echeverri, Ph.D., CEO/CSO, Cenix BioScience GmbH

8:40 KEYNOTE PRESENTATION:
RNAi and Integrated Genomic Approaches to Cancer

David Root, Ph.D., Project Leader, The RNAi Consortium Broad Institute of MIT and Harvard

9:40 Networking Coffee Break in the Exhibit Hall

10:40 RNAi Screening in *Drosophila* Cells: Towards a Global Picture of Cellular Pathways

Stephanie Mohr, PhD, Director, *Drosophila* RNAi Screening Center, Harvard Medical School

11:10 Tumorigenesis and Clinical Outcome are Determined by Network Transformations in Hepatocellular Carcinoma

John R. Lamb, Ph.D., Scientific Director, Department of Genetics, Rosetta Inpharmatics

11:40 Quantifying Challenging Phenotypes in High-throughput Screening Images

Anne Carpenter, Ph.D., Director, Imaging Platform, Broad Institute of Harvard & MIT

12:10 pm RNAi Approach in Guiding the Clinical Trial Design

Holly Yin, Ph.D., Associate Investigator and Head, Cellular Genomics, Translational Genomics Research Institute

12:40 Luncheon Presentation
RNAi Knockdown Model Generation and Characterization

Christine L. Olsson, Ph.D., Commercialization Scientific Director, Taconic Artemis



Tania Sorg, Ph.D., ICS Technical Director, PhenoPro

2:00 Close of Conference

SUGGESTED EVENT PACKAGE

(November 1 - 4)

November 1

Pre-Conference Short Courses:

AND { Strategies for Effective RNAi Screens (SC1)
Strategies to Optimize RNAi Delivery (SC3)

November 2 - 3

Conference:

RNAi for Screening Cellular Pathways and Targets

November 3 - 4

Conference:

RNAi for Developing Targeted Therapeutics



Track 2: HDAC Inhibitors

Developing Molecules for Targeting Oncology and More

November 2-3, 2009

MONDAY, NOVEMBER 2

7:00 am Registration and Morning Coffee

EXPLORING CELLULAR SIGNALING PATHWAYS AND MODE-OF-ACTION

8:30 Chairperson's Opening Remarks

8:40 Targeting Histone Deacetylases in Non-Small Cell Lung Cancer

Pran Datta, Ph.D., Associate Professor, Surgery and Cancer Biology, Vanderbilt University Medical Center

9:10 New Insights into the Mechanisms of HDAC Inhibitors Anti-Cancer Activity

Roberto Rosato, Ph.D., Assistant Professor, Internal Medicine, Massey Cancer Center, Virginia Commonwealth University

9:40 Total Synthesis and Biological Mode of Action of Macrocyclic Histone Deacetylase Inhibitors

Albert Bowers, Ph.D., Research Fellow, Biological Chemistry & Molecular Pharmacology, Harvard Medical School

10:10 Grand Opening Coffee Break in the Exhibit Hall

10:40 Chemical Phylogenetics of Human Histone Deacetylases

James E. Bradner, M.D., M.Sc., Instructor in Medicine, Harvard Medical School and Dana-Farber Cancer Institute

11:10 Anti-inflammatory Effects of HDACi Through Modulation of Foxp3+ Treg Functions

Wayne Hancock, M.D., Ph.D., Professor, Pathology, Children's Hospital of Philadelphia and University of Pennsylvania

11:40 pm Utility of Predictive Biomarkers in the Clinical Development of the HDAC Inhibitor PCI-24781

Sriram Balasubramanian, Ph.D., Director, Translational Research, Pharmacyclics, Inc

12:10 KEYNOTE PRESENTATION: Recent Advances in HDAC Biology

Eric M. Verdin, M.D., Professor of Medicine, University of California, San Francisco

12:40 Luncheon Presentation (Sponsorship Opportunity Available) or Lunch on Your Own

UPDATE ON NOVEL HDAC INHIBITORS

2:20 Chairperson's Remarks

Joel M. Gottesfeld, Ph.D., Professor, Department of Molecular Biology, The Scripps Research Institute

2:25 Therapeutic Applications of Histone Acetylation-Independent Mechanisms of HDAC Inhibitors in Cancer Treatment

Ching-Shih Chen, Ph.D., Professor of Medicinal Chemistry, Internal Medicine and Urology, The Ohio State University

2:55 Design and Development of a Novel Series of HDAC Inhibitors for the Treatment of Cancer and Inflammation

Stephen Shuttleworth, Ph.D., Chief Scientific Officer, Karus Therapeutics Ltd.

3:25 Development of Novel HDAC Inhibitors for CNS Indications

Holger Patzke, Ph.D., Principal Scientist, Neuropharmacology, EnVivo Pharmaceuticals, Inc.

3:55 Networking Refreshment Break in the Exhibit Hall

4:30 Histone Deacetylase Inhibitors as Therapeutics for Neurodegenerative Diseases

Joel M. Gottesfeld, Ph.D., Professor, Department of Molecular Biology, The Scripps Research Institute

5:00 Clinical Development of a Novel Pan-HDAC Inhibitor, Romidepsin, From Phase I Through the New Drug Application (NDA)

Elizabeth Faust, Ph.D., Senior Director, Medical Affairs, Gloucester Pharmaceuticals



5:15 Discovery and Pre-clinical Profile of Novel Potent HDAC Inhibitors

Shridhar Narayanan, Ph.D., Senior Vice President, Biology, Orchid Research Laboratories Limited

5:45 Happy Hour in the Exhibit Hall

7:00 Close of Day

TUESDAY, NOVEMBER 3

7:30 Continental Breakfast Breakout Discussion Sessions

PROGRESS IN THE CLINIC

8:30 Chairperson's Remarks

Sriram Balasubramanian, Ph.D., Director, Translational Research, Pharmacyclics, Inc.

8:40 Discovery of SB939, an HDAC Inhibitor with Class-Leading Properties

Haishan Wang, Ph.D., Group Leader, Chemistry Discovery, S*Bio Pte Ltd.

9:10 Belinostat: A Pan HDAC Inhibitor with Clinical Potential in Both Hematological Malignancies and Solid Tumors

Steven Butcher, Chief Operating Officer, TopoTarget A/S

Richard Penson, Massachusetts General Hospital

9:40 Networking Coffee Break in the Exhibit Hall

10:40 HDAC Inhibitor Entinostat Sensitizes ER α -negative MDA-MB-231 Tumors to Respond to Aromatase Inhibitor Letrozole

Angela Brodie, Ph.D., Professor of Pharmacology and Experimental Therapeutics, University of Maryland School of Medicine

11:10 JNJ-26481585 – Development of a Novel Second Generation Oral Pan-HDAC Inhibitor for Anti-Cancer Therapy

Janna Sand-Dejmek, M.D., Ph.D., Senior Scientist, Oncology Biomarkers, Ortho Biotech Oncology Research & Development

11:40 A Clinical Update on the Development of Panobinostat

Peg Squier, MD, PhD, Global Medical Affairs, Oncology, Senior Director, Novartis Pharmaceuticals Corporation

12:10 pm Improving Outcomes for Lung Cancer with HDAC Inhibitors

Suresh Ramalingam, M.D., Associate Professor of Hematology-Oncology, Emory University School of Medicine

12:40 Close of Conference

SUGGESTED VENT PACKAGE

(November 2 – 4)

November 2 - 3

Conference:
HDAC Inhibitors

November 3 - 4

Conference:
Kinase Inhibitors

Track 3: Ion Channels as Therapeutic Targets

A Flood of Potential for Drug Discovery

November 2-3, 2009

SUNDAY, NOVEMBER 1

Recommended Short Courses*

12:00 pm - 3:00 pm Targeting GPCRs and Ion Channels with Antibodies (SC2)*

3:30 pm - 6:30 pm Structure Based Design of Ion Channels (SC5)*

*Separate Registration Required; Please See Page 3 for Details

MONDAY, NOVEMBER 2

7:00 am Registration and Morning Coffee

KEYNOTE SESSION

8:30 Chairperson's Opening Remarks



8:40 The Challenges of Targeting Ion Channels for Therapeutic Benefit

Gregory J. Kaczorowski, Ph.D., Adjunct Professor, Physiology and Pharmacology, New Jersey Medical School; Adjunct Professor, Physiology and Biophysics, Robert Wood Johnson Medical School



9:10 Lead Generation and Postdocs in the Pharmaceutical Industry – Lessons Learned

Michael Dabrowski, Ph.D., Head, Global Ion Channel Initiative, AstraZeneca R&D



9:40 Ion Channel Drug Targets

David Clapham, M.D., Ph.D., Aldo R. Castañeda Professor of Cardio-vascular Research, Investigator, Howard Hughes Medical Institute

10:10 Grand Opening Coffee Break in the Exhibit Hall

STRUCTURAL STUDIES

10:40 Expression and Purification of Human TRPV1 for Structural Studies

Alla Korepanova, Ph.D., Department of Structural Biology, GPRD, Abbott Laboratories

11:10 Structural Insights into the Function of TRPV Channels

Rachelle Gaudet, Ph.D., Associate Professor, Department of Molecular and Cellular Biology, Harvard University

IMPROVING LEAD GENERATION

11:40 Negotiation of HERG Liabilities via a 3D *in silico* Model: A Case Study

Mark Slack, Ph.D., Senior Scientist, Cellular Assays, Evotec, AG



12:10 pm Hits Validation Using Endogenous Ion Channels Expressed on Human CD4+ T Cells

Melisa Ho, Ph.D., Senior Research Scientist, Wyeth Research

12:40 Luncheon Presentation (Sponsorship Opportunity Available) or Lunch on Your Own

ION CHANNEL CARDIAC SAFETY

2:20 Chairperson's Remarks

2:25 **Cardiovascular Arrhythmia Safety in Drug Development, Inhibition of the Late I_{na} Current to Stabilize Ventricular Repolarization, and Late I_{na} as a Therapeutic Target**

Philip Sager, M.D., Vice President, Clinical Research, Gilead Sciences, Inc.

Luiz Belardinelli, Ph.D., Senior Vice President, Pharmacology and Translational Biomedical Research, CV Therapeutics, Inc.

2:55 **Ion Channels as Lipid Mediators in Brain Disease**

David R. Harder, Ph.D., Associate Dean for Research, The Medical College of Wisconsin

EMERGING THERAPEUTIC TARGETS

3:25 **Title to be Announced**

Derek J. Trezise, Ph.D., Director, Biological Reagents & Assay Development, GlaxoSmithKline

3:55 **Networking Refreshment Break in the Exhibit Hall**

4:30 **Calcium Channelopathies in Neurological Diseases**

Philippe Lory, Ph.D., Institut de Génomique Fonctionnelle, Département de Physiologie, CNRS

5:00 **Sponsored Presentation** (Opportunity Available)

5:15 **Ion Channels in Metabolic Diseases**

Chuan-Chu Chou, Ph.D., Research Fellow, Schering Plough Research Institute

5:45 **Happy Hour in the Exhibit Hall**

7:00 **Close of Day**

TUESDAY, NOVEMBER 3

7:30 am Continental Breakfast Breakout Discussion Sessions

LEADING EDGE TARGETS

8:30 **Chairperson's Remarks**

8:40 **Target Occupancy Studies - Preclinical Decision-making Data Amenable to Clinical Translation**

Sarah Grimwood, Ph.D., Group Lead, Neuroscience Translational Biomarkers, Pfizer, Inc.

9:10 **Evaluation of Available Technologies for Ligand-gated Ion Channel Safety Profiling and Screening**

Gul Erdemli, M.D., Ph.D., Head, Ion Channel Group, Novartis Institutes for BioMedical Research, Inc.

9:40 **Networking Coffee Break in the Exhibit Hall**

10:40 **CRAC Channels in Lymphocyte Function: Lessons from STIM1 and ORAI1 Deficient Human Patients and Mice**

Stefan Feske, M.D., Assistant Professor, Department of Pathology, New York University, Langone Medical Center

11:10 **Perspectives on TRPA1 as a Pain Target: Challenges and Progress**

Regina Reilly, Ph.D., Senior Group Leader, Neuroscience Discovery, Abbott Laboratories

11:40 **Chloride Channels are Drug Targets**

Alan S. Verkman, M.D., Ph.D., Professor, Department of Medicine and Physiology, University of California, San Francisco

12:10 pm **Ion Channels as Mediators of Urinary Bladder Overactivity**

Kevin S. Thorneloe, Ph.D., Investigator, Metabolic Pathways CEDD, GlaxoSmithKline Pharmaceuticals

12:40 **Close of Conference**

SUGGESTED VENT PACKAGE

(November 1 - 4)

November 1

Pre-Conference Short Courses:

Targeting GPCRs and Ion Channels with Antibodies (SC2)
AND Structure-Based Design of Ion Channels (SC5)

November 2 - 3

Conference:

Ion Channels as Therapeutic Targets

November 3 - 4

Conferences:

OR Kinase Inhibitors
Targeting Diabetes with Novel Therapeutics

Track 4: GPCR-Based Drug Discovery

New Screening and Optimization Strategies

November 2-3, 2009

SUNDAY, NOVEMBER 1

Recommended Short Courses*

12:00 pm - 3:00 pm Targeting GPCRs and Ion Channels with Antibodies (SC2)*

3:30 pm - 6:30 pm Structure Based Design of Ion Channels (SC5)*

*Separate Registration Required; Please See Page 3 for Details

MONDAY, NOVEMBER 2

7:00 am Registration and Morning Coffee

APPLYING STRUCTURE-BASED KNOWLEDGE TO GPCR DRUG DISCOVERY

8:30 Chairperson's Opening Remarks

Sidney W. Topiol, Ph.D., Associate Director, Computational Chemistry, Lundbeck Research USA, Inc.

8:40 KEYNOTE PRESENTATION

Key Challenges in Understanding GPCR Structure and Function for Drug Discovery

Graeme Milligan, Ph.D., Professor of Neuroscience and Molecular Pharmacology, University of Glasgow



9:10 The Impact of Recent X-Ray Structure Determinations on Structure-based Drug Design for GPCRs and other CNS Targets

Sidney W. Topiol, Ph.D., Associate Director, Computational Chemistry, Lundbeck Research USA, Inc.

9:40 The Structure of G Protein Coupled Receptors: Implications for Signaling and Pharmacology

Gebhard F. X. Schertler, Ph.D., Senior Scientist, Group Leader, MRC Laboratory of Molecular Biology, Cambridge, UK

10:10 Grand Opening Coffee Break in the Exhibit Hall

10:40 Mapping Ligand Specific States for Drug Design in GPCRs
Nagarajan Vaidehi, Ph.D., Professor of Immunology, Beckman Research Institute of the City of Hope

11:10 Monitoring the Multiple Signaling Pathways of GPCRs: Insights into the Molecular Determinants of Ligand-Biased Signaling

Michel Bouvier, Ph.D., Professor, Biochemistry, Institute for Research in Immunology and Cancer, University of Montreal

11:40 Using Stabilised GPCRs to Enable Structure Based Drug Discovery

Fiona Marshall, Ph.D., Founder and Chief Scientific Officer, Heptares Therapeutics Limited

12:10 pm Sponsored Presentations

(Sponsorship Opportunity Available)

12:40 Luncheon Presentation (Sponsorship Opportunity

Available) or **Lunch on Your Own**

NEW METHODS FOR PROBING OR SCREENING GPCRS

2:20 Chairperson's Remarks

Alice (Yu) Chen, Ph.D., Group Leader, Drug Discovery, Genomics Institute, Novartis Research Foundation

2:25 Targeting GPCR Activity: Conventional and Novel Label-free cAMP Assays

Sandra Siehler, Ph.D., Research Investigator II, Novartis Institute for BioMedical Research

2:55 Hit Identification Practices for GPCR Targets at Bristol-Myers Squibb Company

Neil Burford, Ph.D., Senior Research Investigator, Lead Discovery, Bristol-Myers Squibb Company

3:25 Allosteric Regulation of Agonist and Inverse Agonist Binding to Monomeric GPCRs by G Proteins

Roger Sunahara, Ph.D., Assistant Professor, Pharmacology, University of Michigan Medical School

3:55 Networking Refreshment Break in the Exhibit Hall

4:30 Pepducins – Novel Mediators of GPCR Signaling

Stephen Hunt, III, Ph.D., Senior Vice President, Discovery Research, Ascent Therapeutics

5:00 Testing the Hypothesis of Allosteric Compound Selectivity through Large Scale Selectivity-Profiling

Blaine Armbruster, Ph.D., Manager, GPCR Drug Discovery, Millipore Corporation

5:15 Membrane-tethered Ligands Provide a Novel Strategy for Modulating GPCR Function

Alan S. Kopin, M.D., Professor of Medicine, Director, Molecular Pharmacology Research Center, Tufts University Medical

5:45 Happy Hour in the Exhibit Hall

7:00 Close of Day



TUESDAY, NOVEMBER 3

7:30 am Continental Breakfast Breakout Discussion Sessions

(visit www.discoveryontarget.com for more information)

OPTIMIZING GPCR-CANDIDATES FOR CNS TARGETS AND CALCIUM REGULATORS

8:30 Chairperson's Remarks

Sandra Siehler, Ph.D., Research Investigator II, Novartis Institute for BioMedical Research

8:40 CGRP Receptor Antagonists for the Acute Treatment of Migraine

Donnette Staas, Ph.D., Senior Research Fellow, Medicinal Chemistry, Merck Research Laboratories

9:10 Optimization and Mechanism of Action Studies of Allosteric Modulators of Calcium-Regulation

Jeff Reagan, Ph.D., Scientific Director, Amgen

9:40 Networking Coffee Break in the Exhibit Hall

10:40 Case Study of Preladenant, an A2A Antagonist for the Treatment of Parkinson's Disease

Andy Stamford, Ph.D., Director, Chemical Research, Schering Plough Research Institute

11:10 Pimavanserin: From Target to Clinic Using Sensitive, HTP and Quantitative Drug Discovery Technologies

Doug Bonhaus, Ph.D., Vice President, Biosciences, ACADIA Pharmaceuticals, Inc.

11:40 Development of a Negative Regulator of mGlu5R for Parkinson's

Simon Jones, Ph.D., Vice President, Biology and ADMET, Epix Pharmaceuticals

12:10 pm Discovery of GPCR Ligands for GPR3, a GPCR Modulating Amyloid Secretion in Alzheimer's Disease

David Fischer, Ph.D., Director, Biology, Galapagos

12:40 Close of Conference

SUGGESTED VENT PACKAGE

(November 1 – 4)

November 1

Pre-Conference Short Courses:

AND { Targeting GPCRs and Ion Channels with Antibodies (SC2)
Combating Diabetes with Strategies for Enhanced Pancreatic Beta

OR { Structure-Based Design of Ion Channels (SC5)

November 2 - 3

Conference:
GPCR-Based Drug
Discovery

November 3 - 4

Conference:
Targeting Diabetes
with Novel
Therapeutics

Track 5: RNAi for Developing Targeted Therapeutics

How to Optimize Design and Delivery to Transition from the Lab to the Clinic

November 3-4, 2009

SUNDAY, NOVEMBER 1

Recommended Short Courses*

12:00 pm - 3:00 pm Strategies for Effective RNAi Screens (SC1)*

3:30 pm - 6:30 pm Strategies to Optimize RNAi Delivery (SC3)*

*Separate Registration Required; Please See Page 3 for Details

TUESDAY, NOVEMBER 3

12:30 pm Registration

CHALLENGES IN RNAi DELIVERY

2:00 Chairperson's Opening Remarks

Christina Rondinone, Ph.D., Director, Research, Metabolic Diseases, Hoffmann-La Roche Inc.

2:10 Delivery is in the Details

Catherine J. Pachuk, Senior Director, Delivery Biology, Pfizer Research Technology Center

2:40 Stem Cells as a Non-Immunogenic Vehicle for Delivery of siRNA

Peter R. Brink, Ph.D., Professor and Chair, Department of Physiology and Biophysics, Stony Brook University

3:10 Nanoparticles for Controlled and Targeted Delivery of siRNA

Mark Saltzman, Ph.D., Chair, Department of Biomedical Engineering, Yale University

3:40 Networking Refreshment Break in the Exhibit Hall

4:20 A Biodegradable, Biocompatible, Sustained Release System for RNAi Delivery

Seth D. Feuerstein, M.D., J.D., President, Carigent Therapeutics

4:50 Highly Efficient Delivery of RNAi to Neurons *in Vivo* Using NeuroVex

 **NeuroVex**
Target Validation & Functional Genomics

Anna-Maria Anesti, Ph.D., Product Development Director, NeuroVex, BioVex Inc.

Suzanne Thomas, Ph.D., Director of Project Management, NeuroVex, BioVex Inc.

5:20 Cell Type-specific siRNA Delivery and the Treatment of Disease

Derek M. Dykxhoorn, Ph.D., Assistant Professor, University of Miami School of Medicine

5:50 Combinatorial Development of Synthetic siRNA Delivery Systems

Daniel Anderson, Ph.D., Research Associate, Massachusetts Institute of Technology

6:20 Close of Day

WEDNESDAY, NOVEMBER 4

7:30 am Continental Breakfast Breakout Discussions

CHALLENGES IN THE CLINIC

8:35 Chairperson's Remarks

Bob D. Brown, Ph.D., Senior Vice President, Research, Dicerna Pharmaceuticals Corp.

8:40 Reversal of Drug Resistance in Cancer: Dual Sequential Treatment with Targeted si/shRNA and Drug Packaged Nanocells

Himanshu Brahmabhatt, Ph.D., Joint Chief Executive Officer and Director, Cancer Therapeutics, EnGeneIC Pty. Ltd.

9:10 Title to be Announced

Elena Feinstein, M.D., Ph.D., Chief Scientific Officer, Quark Pharmaceuticals, Inc.

9:40 Title to be Announced

Klaus Giese, Ph.D., Chief Scientific Officer, Silence Therapeutics plc


10:10 Networking Coffee Break in the Exhibit Hall

10:55 Development of Novel RNAi Therapeutic Compounds and *In Vivo* Delivery Approaches

Dmitry Samarsky, Ph.D., V.P., Technology Development, RXi Pharmaceuticals

11:25 KEYNOTE PRESENTATION

RNAi: Developing A New Therapeutic Platform

 John M. Maraganore, Ph.D., Chief Executive Officer, Alnylam Pharmaceuticals

11:55 Panel Discussion: Addressing the Clinical Challenges Associated with RNAi Therapeutics

12:25 pm Luncheon Presentation (Sponsorship Opportunity Available) or Lunch on Your Own

NEW FORMULATIONS AND GENE SILENCING OPTIONS

1:55 Chairperson's Remarks

Dmitry Samarsky, Ph.D., V.P., Technology Development, RXi Pharmaceuticals

2:00 siRNA Construct and Delivery for Effective RNAi

Shaguna Seth, PhD, Director, Pharmacology and Toxicology, Discovery Research and Pharmaceutical Development, MDRNA Inc.

2:30 Novel Cationic Liposome Formulation for RNAi-based Validation of Therapeutic Targets in Rheumatoid Arthritis

Florence Apparailly, Ph.D., Senior Scientist, INSERM U844

3:00 Networking Ice Cream Refreshment Break in Exhibit Hall (Last Chance for Viewing)

3:40 siRNA-Based Topical Microbicides Targeting Sexually Transmitted Diseases

Deborah Palliser, Ph.D., Assistant Professor, Albert Einstein College of Medicine

4:10 Nuclear Gene Silencing with U1 Adaptor Oligonucleotides

Sam Gunderson, Ph.D., Associate Professor, Department of Molecular Biology and Biochemistry, Rutgers University

4:40 Locked Nucleic Acid-based Oligonucleotides (LNA-ONs) as RNA Antagonists for the Control of Cancer

Lee Greenberger, Ph.D., Vice President, Research, Enzon Pharmaceuticals, Inc.

5:10 Close of Conference

SUGGESTED VENT PACKAGE

(November 1 - 4)

November 1

Pre-Conference Short Courses:

Strategies for Effective RNAi Screens (SC1)
AND Strategies to Optimize RNAi Delivery (SC3)

November 2 - 3

Conference:

RNAi for Screening Cellular Pathways and Targets

November 3 - 4

Conference:

RNAi for Developing Targeted Therapeutics

Web Partners:



DiscoveryOnTarget.com



Online: www.DiscoveryOnTarget.com



Email: reg@healthtech.com



Fax: 781-972-5425

Track 6: Kinase Inhibitors

Moving from Discovery to Development

November 3-4, 2009

SUNDAY, NOVEMBER 1

Recommended Short Courses*

12:00 pm - 3:00 pm Targeting GPCRs and Ion Channels with Antibodies (SC2)

*Separate Registration Required; Please See Page 3 for Details

TUESDAY, NOVEMBER 3

12:30 pm Registration

2:00 Chairperson's Opening Remarks

2:10 KEYNOTE PRESENTATION

Safety and Toxicology Challenges on the Way to a Kinase Inhibitor Drug Development

Anja J. Stauber, Ph.D., DABT, Research Advisor, Cancer/Endocrine Safety Assessment, Eli Lilly and Company

DEVELOPMENT – LESSONS LEARNED

2:40 Developing a Novel Checkpoint Kinase Inhibitor

Sonya Zabudoff, Ph.D. Associate Director, Cancer Bioscience, AstraZeneca R&D

3:10 Aurora A Inhibitor MLN8237: From Discovery to Development

Jeffrey Ecsedy, Ph.D. Senior Scientist, Discovery Chemistry, Millennium, The Takeda Oncology Co.

3:40 Networking Refreshment Break in the Exhibit Hall

4:20 Title to be Announced

Peter A. Petillo, Ph.D., Senior Vice President, Deciphera Pharmaceuticals, LLC

IMPROVING EFFICACY

4:50 Comparison of *in vitro* and Cellular IC50 Inhibitory Profiles of 7 Clinical Kinase Inhibitors on 16 Oncologically Relevant Kinases

Jan E. Ehlert, Ph.D., Group Leader, Drug Development, ProQinase

5:05 Sponsored Presentation

(Sponsorship Opportunity Available)

5:20 Identifying Allosteric Modulators of Pyruvate Kinase Orthologs with Quantitative High-throughput Screening

Douglas Auld, Ph.D., Group Leader, NIH Chemical Genomics, National Institute of Health/ NHGRI

5:50 Radiosensitize Human Cancer Cells by an scFv against the DNA-Dependent Protein Kinase

Shuyi Li, M.D., Ph.D., Research Scientist, Program in Cancer Biology and Gene Regulation, Institute of Molecular Medicine and Genetics, Medical College of Georgia

6:20 Close of Day



WEDNESDAY, NOVEMBER 4

7:30 am Continental Breakfast Breakout Discussions

KINASE INHIBITOR CHEMISTRY

8:35 Chairperson's Remarks

8:40 Structure-Guided Design of AP24534, a Potent Orally Active Inhibitor BCR-ABL315I and other Resistant Mutants

William Shakespeare, Ph.D., Vice President, Drug Discovery, ARIAD Pharmaceuticals, Inc.

9:10 Cellular Target Profiling and Quantitative Phosphoproteomics Reveal Insight into a Drug's Efficiency and Cellular Mode of Action



Jutta Fritz, Ph.D., Head, Technology and Business Development, KINAXO Biotechnologies

9:40 The Discovery and Optimization of Highly Selective p38 Inhibitors

Martha J. Kelly, Ph.D., Senior Director, Chemistry, Locust Pharmaceuticals

10:10 Networking Coffee Break in the Exhibit Hall

ADVANCES IN TARGETING TUMORS

10:55 CX-4945, a First in Class Selective Inhibitor of CK2, Effectively Blocks Multiple CK2-Mediated Signaling Pathways, including Akt, and Demonstrates Significant Antiproliferative and Antitumor Activities

Kenna Anderes, Ph.D., Vice President, Cancer Biology, Cylene Pharmaceuticals

11:25 Cediranib: a new and potent pan-VEGFR tyrosine kinase inhibitor that is active in multiple tumor types

Ursula Matulonis, M.D., Assistant Professor, Medicine, Harvard Medical School, Dana-Farber Cancer Institute

11:55 Development of an Antibody Drug Conjugate Targeting The EphA2 Receptor Tyrosine Kinase

Dowdy Jackson, Ph.D., Scientist, MedImmune

12:25 pm Luncheon Presentation (Sponsorship Opportunity Available) **or Lunch on Your Own**

BEYOND CANCER – NOVEL EMERGING TARGETS

1:55 Chairperson's Remarks

2:00 Targeting Bruton's Tyrosine Kinase

Lee Honigberg, Ph.D., Director, Cancer Biology, Pharmacyclics

2:30 Know Pain, Know Gain: Development of a Selective Epsilon PKC Inhibitor for the Treatment of Pain

James Tomlinson, Ph.D., Associate Scientific Director, Molecular and Integrative Pharmacology, KAI Pharmaceuticals, Inc.

3:00 Networking Ice Cream Refreshment Break in Exhibit Hall (Last Chance for Viewing)

3:40 Targeting Diabetes

Alan R. Saltiel, Ph.D., Mary Sue Coleman Director, Life Sciences Institute; John Jacob Abel Professor, Internal Medicine and Physiology, Life Sciences Institute, University of Michigan

4:10 Targeting Protein Kinases in CNS Discovery

D. Martin Watterson, Ph.D., J.G. Searle Professor & Co Director, Center for Drug Discovery & Chemical Biology, Northwestern University

4:40 Title to be Announced

M. Dror Michaelson, M.D., Ph.D., Massachusetts General Hospital Cancer Center

5:10 Close of Conference

SUGGESTED VENT PACKAGE

(November 1 – 4)

November 1

Pre-Conference Short Courses:
Targeting GPCRs and Ion Channels with Antibodies (SC2)

November 2 - 3

Conference:
HDAC Inhibitors

November 3 - 4

Conference:
Kinase Inhibitors

Track 7: Targeting Diabetes with Novel Therapeutics

Strategically Advancing Clinical Compounds

November 3-4, 2009

TUESDAY, NOVEMBER 3

12:30 pm Registration

TARGETING DIABETES AND OBESITY TOGETHER

2:00 Chairperson's Opening Remarks

Reid Huber, Ph.D., Executive Director, Metabolic Endocrine Drug Development, Incyte Corporation

2:10 Modulating Lipid Metabolism

Cristina Rondinone, Ph.D., Director, Research, Metabolic Diseases, Roche Pharmaceuticals

2:40 FGF21 for Treatment of Metabolic Diseases

Jesper Gromada, Ph.D., Executive Director, Cardio-Vascular Metabolic Disease Area, Novartis Institutes for BioMedical Research

3:10 The Tipping Point between Life and Death of ER Stressed Pancreatic Beta Cells

Fumihiko Urano, M.D., Ph.D., Associate Professor of Molecular Medicine, University of Massachusetts Medical School

3:40 Networking Refreshment Break in the Exhibit Hall

4:20 Liver-directed Thyroid Beta Agonist for Targeting Cardio-metabolic Disease

Rebecca Taub, M.D., Senior Vice President, Research & Development, VIA Pharmaceuticals

4:50 Sponsored Presentation

(Sponsorship Opportunity Available)

5:20 Targeting the Gut for the Treatment of Metabolic Diseases

Andrew Swick, Ph.D., Senior Consultant, Illuminate BioPharma Consulting, LLC

5:50 Inhibiting Enterocytic MTP for Treatment of Diabetes and Metabolic Syndrome

Paul Sweetnam, Ph.D., Chief Scientific Officer, Surface Logix

6:20 Close of Day

WEDNESDAY, NOVEMBER 4

7:30 am Continental Breakfast Breakout Discussions

DRUG DEVELOPMENT CHALLENGES

8:35 Chairperson's Remarks

Andrew Swick, Ph.D., Senior Consultant, Illuminate BioPharma Consulting, LLC

8:40 Development of the First FDA-approved Dopamine Agonist for the Treatment of Type 2 Diabetes

Anthony H. Cincotta, Ph.D., President and Chief Scientific Officer, VeroScience

9:10 Is my Lead Diabetes Candidate "Developable" – Focusing on Biopharmaceutical and Formulation Issues from the Start

Akash Jain, Ph.D., Principal Scientist, Chemical & Pharmaceutical Profiling, Novartis Institutes for Biomedical Research

9:40 Update on Next Generation Incretin-Based Therapies

Speaker to be Announced

10:10 Networking Coffee Break in the Exhibit Hall

10:55

KEYNOTE PRESENTATION

Cardiovascular Outcome Studies of Diabetes Drugs

Steven E. Nissen, M.D., M.A.C.C., Chairman, Department of Cardiovascular Medicine, Cleveland Clinic Foundation



11:40 PANEL SESSION: Clinical Landscape for New Diabetes Drug Candidates

Moderator: Steven Nissen, M.D., M.A.C.C., Chairman, Department of Cardiovascular Medicine, Cleveland Clinic Foundation

- What will the standard diabetes regimen of the future look like? Which combinations are likely to have best safety profile, efficacy and ease of use?
- Glucose lowering – should that be the main goal of therapies? What are other possible end points?
- CV toxicity – where to draw the line?
- Incretin based therapies and their CV profile – are there better options?

12:25 pm Luncheon Presentation (Sponsorship Opportunity Available) or Lunch on Your Own

CLINICAL CANDIDATES

1:55 Chairperson's Remarks

Rebecca A. Taub, M.D., Senior Vice President, Research & Development, VIA Pharmaceuticals

2:00 DB959: A Novel, Dual PPAR delta/gamma Agonist for the Treatment of Type 2 Diabetes

Mary Kay Delmedico, Ph.D., Project Leader, Dara Biosciences

2:30 ARRY-403: A Glucokinase Activator with Excellent Efficacy in Multiple Models of Type 2 Diabetes

Thomas D. Aicher, Ph.D., Principal Research Investigator, Medicinal Chemistry, Array BioPharma, Inc.

3:00 Networking Ice Cream Refreshment Break in Exhibit Hall (Last Chance for Viewing)

3:40 Targeting Sodium-Glucose Co-transporter 2: Knockout and Pharmacology program of LX4211

Melanie K. Shadoan, Ph.D., Senior Scientist, Metabolism and Cardiology, Lexicon Pharmaceuticals, Inc.

4:10 A Diabetes Clinical Candidate Against a New Target: Soluble Epoxide Hydrolase

D. Euan MacIntyre, Ph.D., Senior Vice President, Drug Discovery, Arete Therapeutics

4:40 Clinical Results on a 2nd Generation FBPase Inhibitor (MB07803) for the Treatment of Type 2 Diabetes

Barry Gumbiner, M.D., Vice President, Clinical Development & Chief Medical Officer, Metabasis

5:10 Close of Conference

SUGGESTED VENT PACKAGE

(November 1 – 4)

November 1

Pre-Conference Short Courses:

- AND { Targeting GPCRs and Ion Channels with Antibodies (SC2)
Combating Diabetes with Strategies for Enhanced Pancreatic

November 2 - 3

Conferences:

- Ion Channels as Therapeutic Targets
OR { GPCR-Based Drug Discovery

November 3 - 4

Conference:

Targeting Diabetes with Novel Therapeutics

Sponsorship and Exhibit Information

Participating as a Sponsor and Exhibitor at Discovery on Target will allow your company not only showcase your products, services or technologies to over 600 qualified decision-makers, but also put your company in the forefront of this premier drug discovery event. Discovery on Target has perennially attracted leading scientists and executives from throughout the life sciences industry.

SPONSORSHIP OPPORTUNITIES

Sponsorship packages can be customized to fit your unique goals and budget, and can include presentation time, exhibit space, wide-ranging branding opportunities, conference registrations and more!

Agenda Presentations

Speak to a captive audience about your latest technology. This sponsorship includes a 15-minute podium presentation within the scientific agenda as well as exhibit space, onsite branding and access to cooperative marketing efforts by CHI.

Breakfast & Luncheon Presentations

These presentations include a 30-minute podium presentation with a 15-minute Q&A session. Invite session attendees to enjoy breakfast or lunch on your company's behalf while you give your talk.

Invitation-Only VIP Dinner

Sponsor will hand pick its top prospects and invite them to a night of networking at a top local venue. Enjoy a night of discussion and collaboration in a casual atmosphere. CHI will work closely with you to develop an invitation format and guest list.

Other Networking and Promotional Opportunities:

- Branded badge lanyards
- Exhibit hall reception
- Chair drops of company literature
- Branded padfolios
- Branded tote bags
- Tote bag inserts of company literature
- Focus Groups

Exhibit Hall

Exhibitors at Discovery on Target will enjoy facilitated networking opportunities with more than 600 high-level decision-makers. Speak face-to-face with prospective clients and showcase your latest product, service or solution.


To customize your sponsorship or exhibit package, contact:

Jon Stroup, Manager, Business Development


Tel: 781-972-5483 • Email: jstroup@healthtech.com



Attendee Profile



Organization Profile




POSTER DETAILS

Reasons You Should Present Your Research Poster at **Discovery on Target 2009**:

- Your poster will be exposed to over 600 delegates
- Receive \$50 off your registration fee
- Your poster abstract will be included in our conference proceedings link
- Your research will be seen by leaders from top pharmaceutical, biotech, academic and government institutes

Please submit your abstract and register for the meeting. To secure a poster board and inclusion in the conference proceedings link, your abstract must be submitted, accepted and registration paid in full by September 24, 2009.





HOW TO REGISTER: **Online:** www.DiscoveryOnTarget.com

Email: reg@healthtech.com **Phone:** 781-972-5400 **Fax:** 781-972-5425

Yes! Please register me for Discovery on Target

926 F

REGISTRATION INFORMATION

Mr. Ms. Mrs. Dr. Prof.

Name _____

Job Title _____ Div./Dept. _____

Company _____

Address _____

City/State/Postal Code _____

Country _____

Telephone _____

How would you prefer to receive notices from CHI? Email: Yes No Fax: Yes No

Email* _____ Fax _____

*Email is not a mandatory field. However, by excluding your email you will not receive notification about online access to pre-conference presenter materials, conference updates, networking opportunities and requested eNewsletters.

SHORT COURSE PRICING

	Commercial	Academic, Government, Hospital-affiliated
Single Short Course	<input type="checkbox"/> \$645	<input type="checkbox"/> \$345
Two Short Courses	<input type="checkbox"/> \$945	<input type="checkbox"/> \$545

Required – Please select the short course(s) you will attend

- | | |
|---|--|
| 12:00 pm - 3:00 pm | 3:30 pm - 6:30 pm |
| <input type="checkbox"/> SC1 – Strategies for Effective RNAi Screens | <input type="checkbox"/> SC3 – Strategies for Optimizing RNAi Delivery |
| <input type="checkbox"/> SC2 – Targeting GPCRs and Ion Channels with Antibodies | <input type="checkbox"/> SC5 – Structure-Based Design of Ion Channels |

CONFERENCE PRICING

Single Conference Package *Includes access to two (2) conference days (excludes short courses)*

Advance Registration Rate until September 25, 2009	<input type="checkbox"/> \$1395	<input type="checkbox"/> \$695
Registrations after September 25 and on-site	<input type="checkbox"/> \$1595	<input type="checkbox"/> \$795

Required – Please select the 1 conference you will attend

- | | |
|---|--|
| <input type="checkbox"/> Track 1: RNAi for Screening (Nov. 2-3) | <input type="checkbox"/> Track 5: RNAi for Therapeutics (Nov. 3-4) |
| <input type="checkbox"/> Track 2: HDAC Inhibitors (Nov. 2-3) | <input type="checkbox"/> Track 6: Kinase Inhibitors (Nov. 3-4) |
| <input type="checkbox"/> Track 3: Ion Channels for Therapeutic Targets (Nov. 2-3) or | <input type="checkbox"/> Track 7: Targeting Diabetes (Nov. 3-4) |
| <input type="checkbox"/> Track 4: GPCR-Based Drug Discovery (Nov. 2-3) | |

Multi Conference Package *Includes access to three (3) conference days (excludes short courses)*

Advance Registration Rate until September 25, 2009	<input type="checkbox"/> \$1795	<input type="checkbox"/> \$875
Registrations after September 25 and on-site	<input type="checkbox"/> \$1995	<input type="checkbox"/> \$945

Required – Please select the 2 conferences you will attend

- | | |
|--|--|
| <input type="checkbox"/> Track 1: RNAi for Screening (Nov. 2-3) | <input type="checkbox"/> Track 5: RNAi for Therapeutics (Nov. 3-4) |
| <input type="checkbox"/> Track 2: HDAC Inhibitors (Nov. 2-3) | <input type="checkbox"/> Track 6: Kinase Inhibitors (Nov. 3-4) |
| <input type="checkbox"/> Track 3: Ion Channels for Therapeutic Targets (Nov. 2-3) and | <input type="checkbox"/> Track 7: Targeting Diabetes (Nov. 3-4) |
| <input type="checkbox"/> Track 4: GPCR-Based Drug Discovery (Nov. 2-3) | |

POSTER DISCOUNT	<input type="checkbox"/> \$50 off	<input type="checkbox"/> \$50 off
------------------------	-----------------------------------	-----------------------------------

REGISTER 3 - 4th IS FREE

Individuals must register for the same conference or conference combination and submit completed registration form together for discount to apply. Please reproduce this registration form as needed.

GROUP DISCOUNTS AVAILABLE! Special rates are available for multiple attendees from the same organization. For more information on group discounts contact **David Cunningham at 781-972-5472**

- I cannot attend but would like to purchase the Discovery on Target conference CD for \$750 (plus shipping). Massachusetts delivery will include 5% sales tax.
- Please send information on exhibiting and opportunities to present workshops.

PAYMENT INFORMATION

Enclosed is a check or money order payable to Cambridge Healthtech Institute, drawn on a U.S. bank, in U.S. currency.

Invoice me, but reserve my space with credit card information listed below.

Invoices unpaid two weeks prior to conference will be billed to credit card at full registration rate. Invoices must be paid in full and checks received by the deadline date to retain registration discount. If you plan to register on site, please check with CHI beforehand for space availability.

Please charge: AMEX (15 digits) Visa (13-16 digits) MasterCard (16 digits)

Card # _____

Cardholder _____

Signature _____

Cardholder's Address (if different from above) _____

City/State/Postal Code _____

Country _____

Mail Registration to: Cambridge Healthtech Institute

250 First Avenue, Suite 300, Needham, MA 02494 • T: 781.972.5400 • Toll-free in the U.S. 888.999.6288 • F: 781.972.5425

Please refer to the Registration Code below:

Present a Poster and Save \$50!

Cambridge Healthtech Institute encourages attendees to gain further exposure by presenting their work in the poster sessions. To secure a poster board and inclusion in the conference materials, your abstract must be submitted, approved and your registration paid in full by **September 24, 2009**. Register online, or by phone, fax or mail. Indicate that you would like to present a poster and you will receive abstract submission instructions via email. I am interested in presenting a poster at **Discovery on Target**
 Title _____

Yes! I would like to receive a FREE eNewsletter subscription to:

- Weekly Update** The latest industry news, commentary and highlights from BioIT World
- eCliniqua** Innovative management in clinical trials
- Predictive Biomedicine** Informatics tools and strategies driving decisions

CHI Insight Pharma Reports

A series of diverse reports designed to keep life science professionals informed of the salient trends in pharmaceutical technology, business, clinical development, and therapeutic disease markets. For a detailed list of reports, visit InsightPharmaReports.com, or contact Rose LaRaia, rlaraia@healthtech.com, 781-972-5444.

Barnett Educational Services

Barnett is a recognized leader in clinical education, training, and reference guides for life science professionals involved in the drug development process. For more information, visit www.barnettinternational.com.

Additional Registration Details

Each registration includes all conference sessions, posters and exhibits, food functions, and a copy of the conference proceedings link.

Group Discounts

Special rates are available for multiple attendees from the same organization.

Contact David Cunningham at 781-972-5472 to discuss your options and take advantage of the savings.

Handicapped Equal Access

In accordance with the ADA, Cambridge Healthtech Institute is pleased to arrange special accommodations for attendees with special needs. All requests for such assistance must be submitted in writing to CHI at least 30 days prior to the start of the meeting.

Substitution/Cancellation Policy

In the event that you need to cancel a registration, you may:

- Transfer your registration to a colleague within your organization.
- Credit your registration to another Cambridge Healthtech Institute program.
- Request a refund minus a \$100 processing fee per conference.
- Request a refund minus the cost (\$750) of ordering a copy of the CD.

NOTE: Cancellations will only be accepted up to two weeks prior to the conference. Program and speakers are subject to change.

Video and or audio recording of any kind is prohibited onsite at all CHI events.